<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-99644</identifier>
<setSpec>2253-654X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications</dc:title>
<dc:description xml:lang="en">Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity that accounts for less than 5% of the cases of Hodgkin lymphoma (HL) with morphological, immunophenotypical, genetic and clinical behavior traits different from the classic HL. In a minority of patients, the NLPHL course is complicated by a transformation to a non-Hodgkin diffuse large B-cell lymphoma (NHDLBCL) with prognostic and therapeutic implications. Early metabolic changes observed by 18F-FDG PET in patients with HL and NHL, after 1-3 cycles of chemotherapy, predict the final response to treatment and progression-free survival. In the case we are presenting herein, whether NLPHL is transformed to NHDLBCL or the two types of lymphoma co-exist in the same patient, the 18F-FDG PET/CT scan was crucial for the identification of tumor resistance to first line chemotherapy and to guide a second biopsy decision and therefore modify the chemotherapy regimen(AU)</dc:description>
<dc:creator>Prats, E</dc:creator>
<dc:creator>Velilla, J</dc:creator>
<dc:creator>Giraldo, P</dc:creator>
<dc:creator>Ubieto, M. A</dc:creator>
<dc:creator>Rambalde, E. F</dc:creator>
<dc:creator>Santapau, A</dc:creator>
<dc:creator>Banzo, J</dc:creator>
<dc:creator>Parra, A</dc:creator>
<dc:creator>Razola, P</dc:creator>
<dc:creator>Tardin, L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El linfoma de Hodgkin de predominio linfocítico nodular (LHPLN) es una rara entidad que representa menos del 5% de los casos de linfoma de Hodgkin (LH) con rasgos morfológicos, inmunofenotípicos, genéticos y de comportamiento clínico distintos del LH clásico. En una minoría de pacientes, la evolución del LHPLN se complica por transformación a un linfoma no Hodgkin difuso B de células grandes (LNHDBCG) con implicaciones pronósticas y terapéuticas. Los cambios metabólicos precoces observados mediante 18F-FDG PET en pacientes con LH y LNH, después de 1-3 ciclos de quimioterapia predicen la respuesta final al tratamiento y la supervivencia libre de progresión. En el caso que presentamos, tanto si se trata de LHPLN transformado a LNHDBCG o la coexistencia de los dos tipos de linfoma en el mismo paciente, la exploración 18F-FDG PET/TAC fue determinante para identificar la resistencia del tumor a la primera línea de quimioterapia, orientar la toma de una segunda biopsia y modificar el régimen de quimioterapia(AU)</dc:description>
<dc:source>Rev. esp. med. nucl. imagen mol. (Ed. impr.);31(2): 89-92, mar.-abr.2012.</dc:source>
<dc:identifier>ibc-99644</dc:identifier>
<dc:title xml:lang="es">Resistencia al tratamiento de primera línea de quimioterapia en un paciente diagnosticado de linfoma de Hodgkin de predominio linfocítico nodular identificada mediante 18F-FDG PET/TAC: implicaciones diagnósticas y terapéuticas</dc:title>
<dc:subject>^d29271^s22016</dc:subject>
<dc:subject>^d33478^s22038</dc:subject>
<dc:subject>^d22164^s22022</dc:subject>
<dc:subject>^d22164^s22021</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29271^s29166</dc:subject>
<dc:subject>^d9871^s22066</dc:subject>
<dc:subject>^d22497^s22016</dc:subject>
<dc:subject>^d9871^s22045</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d33478</dc:subject>
<dc:subject>^d33478^s22044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201204</dc:date>
</metadata>
</record>
</ibecs-document>
